Fig. 8From: The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in GermanyMultiplicative and additive premiums of orphan drugs with comparable drugs in their indication. Multiplicative and additive premiums of orphan drugs with comparable drugs in their indication are presentedBack to article page